Healthcare Industry News: hemodialysis
News Release - October 5, 2012
AngioDynamics Awarded GPO Contract for Vascular Access ProductsContract With HealthTrust Covers Chronic & Acute Dialysis Catheters
ALBANY, N.Y., Oct. 5, 2012 -- (Healthcare Sales & Marketing Network) -- AngioDynamics (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it has been awarded a contract with HealthTrust Purchasing Group (HealthTrust) covering vascular access products, including its DuraMax chronic dialysis catheter, DuraFlow, DuraFlow 2 and EvenMore chronic hemodialysis catheters, and the Schon XL acute hemodialysis catheter.
The contract became effective on Oct. 1, 2012. AngioDynamics has previously had HealthTrust agreements covering the Company's peripheral vascular and fluid management products. "This is our first vascular access contract with HealthTrust and it will provide their 1,400 member hospitals with access to our quality dialysis products," said AngioDynamics Senior Vice President and GM for U.S. Sales Alan Panzer.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
About HealthTrust Purchasing Group
HealthTrust Purchasing Group, L.P., (www.healthtrustpg.com) headquartered in Brentwood, Tenn., is a group purchasing organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as 10,600 ambulatory surgery centers, physician practices and alternate care sites. With an annual purchasing volume by its members of more than $20 billion, HealthTrust is committed to obtaining the best price for clinically recommended products, ensuring their timely delivery, and continuously evaluating and improving its services to the patients, physicians and clinicians it serves. HealthTrust is closely integrated with the provider-proven capabilities of Parallon Business Solutions (www.parallon.net) which include revenue cycle and business process expertise, workforce management solutions, supply chain services and technology solutions.
AngioDynamics, the AngioDynamics logo, DuraMax, DuraFlow, DuraFlow 2, EvenMore and Schon XL are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2012. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.